Mutations in circulating mitochondrial DNA: Cassandra of oral cancer?
Mutations in circulating mitochondrial DNA: Cassandra of oral cancer? |
|
https://doi.org/10.18632/oncotarget.567
Eugene S. Kandel
|
| 664-665 |
Engineering Enzymatically Activated “Molecular Grenades” for Cancer
Engineering Enzymatically Activated “Molecular Grenades” for Cancer |
|
https://doi.org/10.18632/oncotarget.562
Samuel R. Denmeade,
and John T. Isaacs
|
| 666-667 |
Folate Receptor Alpha: A New Tool in the Diagnosis and Treatment of Lung Cancer
Folate Receptor Alpha: A New Tool in the Diagnosis and Treatment of Lung Cancer |
|
https://doi.org/10.18632/oncotarget.575
Laura D. Wood
|
| 668-669 |
Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma.
Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma. |
|
https://doi.org/10.18632/oncotarget.523
Katsuhiro Uzawa,
Takao Baba,
Fumihiko Uchida,
Masanobu Yamatoji,
Atsushi Kasamatsu,
Yosuke Sakamoto,
Katsunori Ogawara,
Masashi Shiiba,
Hiroki Bukawa,
and Hideki Tanzawa
|
| 670-677 |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing |
|
https://doi.org/10.18632/oncotarget.554
Kalpesh Patel,
Sashidhar R. Yerram,
Nilofer A. Azad,
and Scott E. Kern
|
| 678-685 |
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) |
|
https://doi.org/10.18632/oncotarget.546
Karoly Szepeshazi,
Andrew V Schally,
Gunhild Keller,
Norman L Block,
Daniel Benten,
Gabor Halmos,
Luca Szalontay,
Irving Vidaurre,
Miklos Jaszberenyi,
and Ferenc G Rick
|
| 686-699 |
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes |
|
https://doi.org/10.18632/oncotarget.587
Ruchi Singhal,
and Eugene S. Kandel
|
| 700-708 |
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas |
|
https://doi.org/10.18632/oncotarget.588
Yuchen Jiao,
Patrick J. Killela,
Zachary J. Reitman,
B.Ahmed Rasheed,
Christopher M. Heaphy,
Roeland F. de Wilde,
Fausto J. Rodriguez,
Sergio Rosemberg,
Sueli Meiko Obashinjo,
Suely Kazue Nagahashi Marie,
Chetan Bettegowda,
Nishant Agrawal,
Eric Lipp,
Christopher Pirozzi,
Giselle Lopez,
Yiping He,
Henry Friedman,
Allan H. Friedman,
Gregory J. Riggins,
Matthias Holdhoff,
Peter Burger,
Roger McLendon,
Darell D. Bigner,
Bert Vogelstein,
Alan K. Meeker,
Kenneth W. Kinzler,
Nickolas Papadopoulos,
Luis A. Diaz, Jr.,
and Hai Yan
|
| 709-722 |
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma |
|
https://doi.org/10.18632/oncotarget.547
Maria Carmela Speranza,
Véronique Frattini,
Federica Pisati,
Dimos Kapetis,
Paola Porrati,
Marica Eoli,
Serena Pellegatta,
and Gaetano Finocchiaro
|
| 723-734 |
